Background The benefits of triple therapy for chronic obstructive pulmonary disease (COPD)
with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-…

Background Whether the combination of a once-daily inhaled corticosteroid with a once-daily
longacting β 2 agonist is more protective than a once-daily longacting β 2 agonist alone …

Rationale: Radiographically confirmed pneumonia risk with inhaled corticosteroid use in
chronic obstructive pulmonary disease (COPD) has not been assessed to date. Objectives: To …

Background Vilanterol (GW642444M) (VI) is a novel, inhaled, long-acting β 2 agonist with
inherent 24-h activity under development as a once-daily combination therapy with an inhaled …

The aim of this review is to present the clinical data on the efficacy and safety of cilomilast in
patients with chronic obstructive pulmonary disease (COPD). Over 6000 COPD patients …

Background Aerosolized asthma medications with chlorofluorocarbon (CFC) propellants are
being phased out because of environmental concerns about the ozone layer. Medications …

PURPOSE: COPD exacerbations contribute to the morbidity and mortality of COPD. A pooled
post hoc analysis taking into account the frequency and duration of COPD exacerbations …

Rationale: Current GOLD strategy document positions both combination regimens of
inhaled corticosteroid plus a long-acting β 2 -agonist [ICS/LABA] and LABA plus long-acting …

PURPOSE: COPD patients with impaired QOL are more likely to experience exacerbations
and thereby utilize more healthcare resources. The objective of the present analysis was to …

PURPOSE: Patients with COPD are known to be at increased risk of cardiovascular (CV)
disease. To evaluate the CV safety of cilomilast (CIL) in patients with COPD, an integration of …